TY - JOUR
T1 - Labour induction for termination of pregnancy with severe fetal anomalies after 24 weeks’ gestation
T2 - a case series and systematic review of the literature
AU - Kiley, Jessica
AU - Turner, Ashley
AU - Nosal, Catherine
AU - Beestrum, Molly
AU - Dungan, Jeffrey
N1 - Funding Information:
Departmental funds were used to support the study. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors sincerely thank Dr. Lee Shulman for his support and guidance during manuscript preparation.
Publisher Copyright:
© 2022 The European Society of Contraception and Reproductive Health.
PY - 2022
Y1 - 2022
N2 - Purpose: Under some circumstances, individuals choose to undergo pregnancy termination for foetal anomalies in the second half of pregnancy. This report provides objective information on the clinical management of such cases and a systematic review of the literature on labour induction outcomes for third-trimester abortion using mifepristone-misoprostol. Materials and methods: The study is a case series describing outcomes for labour induction abortion for foetal anomalies, at gestational age 24 weeks and beyond. A systematic review was performed, searching PubMed, Embase, and Cochrane databases. Two independent authors reviewed and quality assessed the data from the articles. Results: During a two-year period, 15 patients met inclusion criteria. Fourteen patients received mifepristone and misoprostol, and one received oxytocin. All delivered vaginally. Thirteen patients delivered within 24 hours of the first misoprostol dose, and half delivered within 12 hours. The average interval from misoprostol initiation to foetal expulsion was 15.5 hours in our series. The systematic review identified nine articles for inclusion, all retrospective studies. Labour induction protocols for mifepristone-misoprostol, reporting of gestational age, and key comparisons varied greatly. Conclusions: The case series illustrates successful termination of pregnancy primarily using combined mifepristone-misoprostol. Certainty of current evidence is low, based on the GRADE framework. Future research is necessary on third-trimester outcomes with mifepristone-misoprostol.
AB - Purpose: Under some circumstances, individuals choose to undergo pregnancy termination for foetal anomalies in the second half of pregnancy. This report provides objective information on the clinical management of such cases and a systematic review of the literature on labour induction outcomes for third-trimester abortion using mifepristone-misoprostol. Materials and methods: The study is a case series describing outcomes for labour induction abortion for foetal anomalies, at gestational age 24 weeks and beyond. A systematic review was performed, searching PubMed, Embase, and Cochrane databases. Two independent authors reviewed and quality assessed the data from the articles. Results: During a two-year period, 15 patients met inclusion criteria. Fourteen patients received mifepristone and misoprostol, and one received oxytocin. All delivered vaginally. Thirteen patients delivered within 24 hours of the first misoprostol dose, and half delivered within 12 hours. The average interval from misoprostol initiation to foetal expulsion was 15.5 hours in our series. The systematic review identified nine articles for inclusion, all retrospective studies. Labour induction protocols for mifepristone-misoprostol, reporting of gestational age, and key comparisons varied greatly. Conclusions: The case series illustrates successful termination of pregnancy primarily using combined mifepristone-misoprostol. Certainty of current evidence is low, based on the GRADE framework. Future research is necessary on third-trimester outcomes with mifepristone-misoprostol.
KW - Abortion
KW - labour induction
KW - mifepristone
KW - misoprostol
KW - second trimester
KW - third trimester
UR - http://www.scopus.com/inward/record.url?scp=85135138092&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135138092&partnerID=8YFLogxK
U2 - 10.1080/13625187.2022.2102604
DO - 10.1080/13625187.2022.2102604
M3 - Article
C2 - 35899830
AN - SCOPUS:85135138092
SN - 1362-5187
VL - 27
SP - 486
EP - 493
JO - European Journal of Contraception and Reproductive Health Care
JF - European Journal of Contraception and Reproductive Health Care
IS - 6
ER -